SQZ Biotechnologies (SQZ) Competitors

Scinai Immunotherapeutics (NASDAQ:SCNI) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership.

Is SCNI or SQZ more profitable?

Scinai Immunotherapeutics has a net margin of 0.00% compared to Scinai Immunotherapeutics' net margin of -369.96%. SQZ Biotechnologies' return on equity of 0.00% beat Scinai Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	-49.31%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

Does the MarketBeat Community favor SCNI or SQZ?

SQZ Biotechnologies received 10 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users.

Company	Underperform	Outperform
Scinai Immunotherapeutics	N/A	N/A
SQZ Biotechnologies	Outperform Votes 10 66.67%	Underperform Votes 5 33.33%

Which has preferable earnings and valuation, SCNI or SQZ?

Scinai Immunotherapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	N/A	N/A	-$5.80M	-$3.27	-0.14
SQZ Biotechnologies	$18.16M	0.03	-$79.46M	-$2.61	-0.01

Do insiders & institutionals believe in SCNI or SQZ?

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 6.0% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media refer more to SCNI or SQZ?

In the previous week, Scinai Immunotherapeutics had 5 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 5 mentions for Scinai Immunotherapeutics and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 0.56 beat Scinai Immunotherapeutics' score of 0.00 indicating that Scinai Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Positive
SQZ Biotechnologies	Neutral

Which has more risk and volatility, SCNI or SQZ?

Scinai Immunotherapeutics has a beta of 2.45, meaning that its share price is 145% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.

Do analysts recommend SCNI or SQZ?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Summary

Scinai Immunotherapeutics beats SQZ Biotechnologies on 8 of the 13 factors compared between the two stocks.